Armstrong AW, Mburu S, Gondo GC, Kornyeyeva E, Frade S, Ogdie A. Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study , Drugs Real World Outcomes: 2025
Mayer SE, Kluberg SA, Spence O, Oraichi D, Seifert H, Ali O, Yun H, Simon AL, Ko JS, Hugh C, Her M, Shattuck K, Jamal-Allial A, Djibo DA, Daniels K, Ma Q, McMahill-Walraven CN, Ogilvie RP, Palmsten K, Selvan M, Ziyadeh N, Ogdie A, George MD. Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA , RMD Open, 11: 2025,e005839
Wu A, Zhang A, Guo Y, Liu J, Yang DM, Chada LP, Ogdie A, Reddy SM, Gottlieb AB, Scher JU, Merola JF. Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis , JAMA Dermatol: 2025
Coates LC, Blanco R, Behrens F, Ogdie A, Van den Bosch F, Ranza R, Klionsky Y, Soliman AM, Chen M, Coombs D, Shi L, Urbanik JR, Iyile T, Lippe R, Gossec L. Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies , RMD Open, 11: 2025,e005522
Rice AL, Gillespie S, Sai N, Reddy SM, Merola JF, Haberman RH, Ogdie A, Scher JU. Gaps in Documentation of Psoriatic Domains in General Rheumatologic Practices Compared to Rheumatology-Dermatology Combined Clinics , J Psoriasis Psoriatic Arthritis: 2025
Thrastardottir T, Bjornsson AH, Ogdie A, Hauksdottir A, Kristinsson SY, Gudbjornsson B, Love TJ; ICEBIO. Antimicrobial use and serious infections among psoriatic arthritis patients after initiating tumor necrosis factor inhibitors: a nationwide matched cohort study , J Rheumatol: 2025
Allenzara A, Bush K, Husni ME, Reddy SM, Scher JU, Craig E, Koplin J, Walsh JA, Ogdie A. Diverse Treatment Goals in Psoriatic Arthritis: Insights from participants in the PARC cohort , Arthritis Care Res (Hoboken): 2025
Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA. Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial , Trials, 26: 2025,96
Perez-Chada LM, Gondo G, Grant C, Woodbury M, Kucharik AH, Armstrong AW, Eder L, Mease P, Ogdie A, Strand V, Gottlieb AB, Merola JF. Construct validity of the IDEOM MSK Questionnaire (IDEOM MSK-Q): an instrument to measure musculoskeletal symptoms in patients with psoriatic disease , J Invest Dermatol: 2025
Karmacharya P, Crofford LJ, Byrne DW, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Walsh JA, Ogdie A. Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium , Ann Rheum Dis: 2025
